



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
GRAUPE, et al.

Examiner: Shiao, Rei Tsang

Art Unit: 1626

Application No.: 10/035,783

Filed: December 24, 2001

Title: NOVEL COMPOUNDS AND
COMPOSITIONS AS CATHEPSIN
INHIBITORS

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for
Patents, Alexandria, VA 22313, at 571-273-2885 on

January 3, 2005
Date of Transmission

Signature

CORRECTED ISSUE FEE TRANSMITTAL

Mail Stop ISSUE FEE
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The Entity Status on the Issue Fee Transmittal for the above-referenced US patent application that was timely faxed to the USPTO on November 29, 2005 was incorrect.

Applicants hereby submit a corrected Issue Fee Transmittal with Box 5b checked showing that the Applicant is no longer claiming SMALL ENTITY status (37 CFR 1.27(g)(2)). Applicants believe that the foregoing constitutes a complete and full response to the Notice of Allowance/Issue Fee. The Commissioner is hereby authorized to charge the additional \$700.00 to cover the full non- SMALL ENTITY Issue Fee (37 CFR 1.18 (a)) and any additional required


USAV2001/0081 US NP

PATENT

fees, or credit any overpayment, to Deposit Account No. 18-1982 in the name of Aventis
Pharmaceuticals Inc.

Respectfully submitted,

Dated: January 3, 2006



Joseph D. Rossi, Reg. No.: 47,038
Attorney for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3410
Telefax (908) 231-2626
USAV2001/0081 US NP



2. 2006 3:14PM

AVENTIS US PAT DEPT

NO. 0925 P. 1

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/035,783	
	Filing Date	December 24, 2001	
	First Named Inventor	Michael GRAUPE et al.	
	Art Unit	1626	
	Examiner Name	SHIAO, Rei Tsang	
Total Number of Pages in This Submission	3	Attorney Docket Number	USAV2001/0081 US NP

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Corrected Issue Fee Transmittal
<input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	AVENTIS PHARMACEUTICALS INC.	
Signature		
Printed name	Joseph ROSSI	
Date	January 03, 2006	Reg. No. 47038

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. (USPTO FAX NO. 571-273-2885 ; Total No. of Pages Transmitted: 3)	
Signature	
Typed or printed name	Paul Irvine
Date	January 03, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.